AUA 2018: Outcomes of Synchronous and Metachronous Bilateral Small Renal Masses (4cm)

San Francisco, CA (UroToday.com) The authors presented a study reporting longitudinal outcomes of a population based cohort of patients diagnosed with bilateral small renal masses from a period of over 11 years. Consecutive patients diagnosed with bilateral small renal masses (synchronous or metachronous) of a defined geographical area were recorded in a large database (TUCAN database) between January 2005 and December 2016. Patients were followed during this period using an agreed upon protocol. Clinicopathological characteristics and outcomes of bilateral small renal masses on active surveillance were analyzed and compared to propensity score matched sporadic unilateral small renal masses. Data were analyzed for renal mass growth rate, the rate of intervention and development of metastatic disease and patient survival. 

A total of 1600 patients were diagnosed with renal cancer, of which bilateral small renal masses accounted for 70 (6.6%) cases. Synchronous SRMs were observed in 63 patients, whereas metachronous lesions were found in seven patients during the study period. Metachronous lesion mean time to appearance was 62 months (range, 9 to 149 months). While most cases were sporadic, four were found to be hereditary. Growth rate of bilateral small renal masses did not differ from that of unilateral sporadic small renal masses (Figure 1). Similarly, there were no between group differences for the rate of interventions and survival. 

Figure 1 – Growth rate in unilateral and bilateral small renal masses:
Growth rate in unilateral and bilateral small renal masses

The authors concluded that progression, rate of metastases and survival of patients diagnosed with bilateral small renal masses is similar to those diagnosed with unilateral disease.


Presented by: Professor Ghulam Nabi, Dundee, United Kingdom Nissar Sheikh, Dundee, United Kingdom
Co-Authors: Mohammad Khan, Stephen Lang, Sanjay Pillai, Dundee, United Kingdom

Written by:  Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre @GoldbergHanan at the 2018 AUA Annual Meeting - May 18 - 21, 2018 – San Francisco, CA USA
email news signup